We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

In the TRAVERSE trial, hypothyroid men at high risk of cardiovascular disease who received testosterone had a similar risk of serious cardiovascular adverse events compared to those who received placebo.

A. Michael Lincoffdoctor, vice chair of research, cardiovascular medicine and professor of medicine at the Cleveland Clinic, said at the ENDO 2023 presentation that the results “should facilitate a more informed consideration of the potential benefits and risks of testosterone therapy for middle-aged and older men with hypogonadism.” It was the top story in endocrinology last week.



Testosterone drawing Adobe
In the TRAVERSE trial, hypothyroid men at high risk of cardiovascular disease who received testosterone had a similar risk of serious cardiovascular adverse events compared to those who received placebo. Photo: Adobe Stock

Another top story was about data showing that metformin could reduce the risk of chronic COVID. Researchers found that the risk of chronic COVID was 41.3% lower in overweight or obese metformin users compared to placebo over a 10-month follow-up period.

Read these and other top endocrinology stories below:

TRAVERSE: Men who use testosterone supplements are not at increased risk of CV events

Older men with hypothyroidism and a high risk of cardiovascular disease who received testosterone therapy had similar rates of cardiovascular disease to those who received a placebo, according to results from the TRAVERSE study. Read more.

Metformin may reduce the risk of chronic COVID among adults with obesity

Overweight or obese adults who received metformin soon after a COVID-19 diagnosis had a lower risk of prolonged COVID than those who received a placebo, according to study data. Read more.

Teriparatide delivered by robotic pill provides higher bioavailability than injection

An oral robotic pill may provide an alternative delivery method to subcutaneous injection for teriparatide and other biologics, according to a speaker at ENDO 2023. Read more.

The Coming ‘Renaissance in Endocrinology’: A Conversation with R. Scott Struthers, PhD

R. Scott Struthers, PhD, was in a lab making peptide hormones as a college freshman. That experience launched a career that includes discovering new drugs for endocrine disorders, women’s health and cancer. Read more.

Combined exposure to environmental dioxins assocd hypothyroidism

Using three different statistical models, researchers determined that individual exposure to a combination of 20 dioxins negatively affects thyroid function, according to a presentation at ENDO 2023. Read more.

#Top #Endocrinology #Testosterone #Supplements #reduced #chronic #COVID #risk #metformin #users